Medpace (MEDP) Reaches New 12-Month High and Low at $45.48

Shares of Medpace Holdings Inc (NASDAQ:MEDP) hit a new 52-week high and low on Thursday . The company traded as low as $45.48 and last traded at $45.59, with a volume of 12531 shares. The stock had previously closed at $44.06.

A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Wednesday, March 14th. BidaskClub raised shares of Medpace from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 16th. Wells Fargo & Co decreased their price target on shares of Medpace from $38.00 to $35.00 and set a “market perform” rating for the company in a research report on Wednesday, February 28th. Robert W. Baird set a $35.00 price target on shares of Medpace and gave the stock a “hold” rating in a research report on Tuesday, April 10th. Finally, Mitsubishi UFJ Financial Group reissued a “neutral” rating and issued a $40.00 price objective on shares of Medpace in a research report on Friday, April 20th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $37.83.

The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.66 and a current ratio of 0.66. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of 29.59, a PEG ratio of 1.64 and a beta of 0.22.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, April 30th. The company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.17. The company had revenue of $108.40 million during the quarter, compared to analysts’ expectations of $113.12 million. Medpace had a net margin of 10.37% and a return on equity of 12.50%. The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.34 EPS. analysts anticipate that Medpace Holdings Inc will post 1.89 EPS for the current year.

In other Medpace news, major shareholder Medpace Limited Partnership sold 3,000,000 shares of the company’s stock in a transaction dated Monday, May 7th. The shares were sold at an average price of $35.49, for a total value of $106,470,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 29.50% of the company’s stock.

Several institutional investors have recently modified their holdings of MEDP. Schwab Charles Investment Management Inc. raised its stake in shares of Medpace by 96.9% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 58,066 shares of the company’s stock valued at $2,106,000 after purchasing an additional 28,581 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Medpace in the 4th quarter valued at about $151,000. LSV Asset Management acquired a new stake in shares of Medpace in the 4th quarter valued at about $527,000. First Trust Advisors LP acquired a new stake in shares of Medpace in the 4th quarter valued at about $1,545,000. Finally, Wells Fargo & Company MN raised its stake in shares of Medpace by 90.3% in the 4th quarter. Wells Fargo & Company MN now owns 19,703 shares of the company’s stock valued at $714,000 after purchasing an additional 9,349 shares in the last quarter. Institutional investors and hedge funds own 26.83% of the company’s stock.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply